class = “cf”>
The Wales test, which is already available in the United States, will be administered to around 140,000 volunteers in eight regions of the United Kingdom. The test should be able to detect cancers that are not systematically screened for and find with a high degree of accuracy where the disease is coming from in the body.
NHS chief executive Amanda Pritchard said: “This quick and easy blood test could be the start of a revolution in cancer detection and treatment around the world. The test will increase our chances of finding cancer and treat it before signs and symptoms appear Give people the best chance of survival We can give mentioned.
The NHS trial will be administered to people between the ages of 50 and 77 of different origins and ethnicities. Volunteers should not have been diagnosed with cancer within the past three years. The volunteers will give blood samples again at the mobile testing clinics in the weeks following the test, 12 months later and two years later.
PARTS OF THE GENETIC CODE WILL BE TESTED
class = “cf”>
The test will look for chemical changes in pieces of genetic code that seep into the blood from tumors; it is said to be something that some cancers do long before symptoms appear.
Pritchard said the test could play an important role in its goal of detecting 75% of cancers that are more difficult to diagnose early, such as cancers of the head and neck, intestines, lungs, pancreas and throat, at an early stage that are easier to treat. However, he said the test cannot replace NHS screening programs for breast, cervical and bowel cancers.
The experiment is being carried out by Cancer Research UK and the Cancer Prevention Trials Unit at King’s College London in collaboration with Grail, who developed the Galleri test. Professor Peter Sasieni, director of the unit and principal investigator of the study, said:
“Testing can be a miracle in early detection of cancer and we are excited to be conducting this important research. Cancer screening can detect cancers earlier when they are more likely to be successfully treated, but not all. types of screening. “
The first results of the test are expected by 2023, and if successful, the test could be used from 2024.
A study published in June in Annals of Oncology analyzed how the test worked in 2,823 people with cancer and 1,254 people without cancer.
class = “cf”>
The test correctly identified cancer in 51.5% of cases at all stages of the disease, with a false positive rate of just 0.5%.
The test’s ability to produce a positive result for unscreened tumors, such as cancers of the esophagus, liver, and pancreas, was twice as high (65.6%) as for screened tumors, such as cancers of the breast, intestine, cervix and prostate. About 55% of blood cancers were detected and the tissue in which the cancer was found was identified in 88.7% of cases.
This guide guides gastronomy enthusiasts